{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:23:23Z","timestamp":1790504603380,"version":"4.1.0"},"reference-count":17,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2005,5,1]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> To describe the natural history of nonmetastatic prostate cancer and rising prostate-specific antigen (PSA) despite androgen deprivation therapy. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods:<\/jats:title><jats:p> The 201 patients in this report were the placebo control group from an aborted randomized controlled trial to evaluate the effects of zoledronic acid on time to first bone metastasis in men with prostate cancer, no bone metastases, and rising PSA despite androgen deprivation therapy. Relationships between baseline covariates and clinical outcomes were assessed by Cox proportional hazard analyses. Covariates in the model were baseline PSA, Gleason sum, history of bilateral orchiectomies, regional lymph node metastases at diagnosis, prior prostatectomy, time from androgen deprivation therapy to random assignment, time from diagnosis to random assignment, and PSA velocity. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> At 2 years, 33% of patients had developed bone metastases. Median bone metastasis\u2013free survival was 30 months. Median time to first bone metastases and overall survival were not reached. Baseline PSA level greater than 10 ng\/mL (relative risk, 3.18; 95% CI, 1.74 to 5.80; P &lt; .001) and PSA velocity (4.34 for each 0.01 increase in PSA velocity; 95% CI, 2.30 to 8.21; P &lt; .001) independently predicted shorter time to first bone metastasis. Baseline PSA and PSA velocity also independently predicted overall survival and metastasis-free survival. Other covariates did not consistently predict clinical outcomes. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> Men with nonmetastatic prostate cancer and rising PSA despite androgen deprivation therapy have a relatively indolent natural history. Baseline PSA and PSA velocity independently predict time to first bone metastasis and survival. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2005.01.529","type":"journal-article","created":{"date-parts":[[2005,4,28]],"date-time":"2005-04-28T23:04:27Z","timestamp":1114729467000},"page":"2918-2925","source":"Crossref","is-referenced-by-count":435,"title":["Natural History of Rising Serum Prostate-Specific Antigen in Men With Castrate Nonmetastatic Prostate Cancer"],"prefix":"10.1200","volume":"23","author":[{"given":"Matthew R.","family":"Smith","sequence":"first","affiliation":[{"name":"From the Massachusetts General Hospital, Boston, MA; University of California at Los Angeles, Los Angeles; University of California at San Francisco, San Francisco; Western Clinical Research, Torrance, CA; University of Montreal, Montreal, Canada; University of Maryland, Baltimore, MD; S Florida Medical Research, Aventura, FL; Christchurch Hospital, Christchurch, New Zealand; Peter MacCallum Cancer Institute, Melbourne, Australia; Free University of Brussels, Brussels, Belgium; Novartis Oncology, East..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fairooz","family":"Kabbinavar","sequence":"additional","affiliation":[{"name":"From the Massachusetts General Hospital, Boston, MA; University of California at Los Angeles, Los Angeles; University of California at San Francisco, San Francisco; Western Clinical Research, Torrance, CA; University of Montreal, Montreal, Canada; University of Maryland, Baltimore, MD; S Florida Medical Research, Aventura, FL; Christchurch Hospital, Christchurch, New Zealand; Peter MacCallum Cancer Institute, Melbourne, Australia; Free University of Brussels, Brussels, Belgium; Novartis Oncology, East..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[{"name":"From the Massachusetts General Hospital, Boston, MA; University of California at Los Angeles, Los Angeles; University of California at San Francisco, San Francisco; Western Clinical Research, Torrance, CA; University of Montreal, Montreal, Canada; University of Maryland, Baltimore, MD; S Florida Medical Research, Aventura, FL; Christchurch Hospital, Christchurch, New Zealand; Peter MacCallum Cancer Institute, Melbourne, Australia; Free University of Brussels, Brussels, Belgium; Novartis Oncology, East..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arif","family":"Hussain","sequence":"additional","affiliation":[{"name":"From the Massachusetts General Hospital, Boston, MA; University of California at Los Angeles, Los Angeles; University of California at San Francisco, San Francisco; Western Clinical Research, Torrance, CA; University of Montreal, Montreal, Canada; University of Maryland, Baltimore, MD; S Florida Medical Research, Aventura, FL; Christchurch Hospital, Christchurch, New Zealand; Peter MacCallum Cancer Institute, Melbourne, Australia; Free University of Brussels, Brussels, Belgium; Novartis Oncology, East..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc C.","family":"Gittelman","sequence":"additional","affiliation":[{"name":"From the Massachusetts General Hospital, Boston, MA; University of California at Los Angeles, Los Angeles; University of California at San Francisco, San Francisco; Western Clinical Research, Torrance, CA; University of Montreal, Montreal, Canada; University of Maryland, Baltimore, MD; S Florida Medical Research, Aventura, FL; Christchurch Hospital, Christchurch, New Zealand; Peter MacCallum Cancer Institute, Melbourne, Australia; Free University of Brussels, Brussels, Belgium; Novartis Oncology, East..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Bilhartz","sequence":"additional","affiliation":[{"name":"From the Massachusetts General Hospital, Boston, MA; University of California at Los Angeles, Los Angeles; University of California at San Francisco, San Francisco; Western Clinical Research, Torrance, CA; University of Montreal, Montreal, Canada; University of Maryland, Baltimore, MD; S Florida Medical Research, Aventura, FL; Christchurch Hospital, Christchurch, New Zealand; Peter MacCallum Cancer Institute, Melbourne, Australia; Free University of Brussels, Brussels, Belgium; Novartis Oncology, East..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Wynne","sequence":"additional","affiliation":[{"name":"From the Massachusetts General Hospital, Boston, MA; University of California at Los Angeles, Los Angeles; University of California at San Francisco, San Francisco; Western Clinical Research, Torrance, CA; University of Montreal, Montreal, Canada; University of Maryland, Baltimore, MD; S Florida Medical Research, Aventura, FL; Christchurch Hospital, Christchurch, New Zealand; Peter MacCallum Cancer Institute, Melbourne, Australia; Free University of Brussels, Brussels, Belgium; Novartis Oncology, East..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Murray","sequence":"additional","affiliation":[{"name":"From the Massachusetts General Hospital, Boston, MA; University of California at Los Angeles, Los Angeles; University of California at San Francisco, San Francisco; Western Clinical Research, Torrance, CA; University of Montreal, Montreal, Canada; University of Maryland, Baltimore, MD; S Florida Medical Research, Aventura, FL; Christchurch Hospital, Christchurch, New Zealand; Peter MacCallum Cancer Institute, Melbourne, Australia; Free University of Brussels, Brussels, Belgium; Novartis Oncology, East..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman R.","family":"Zinner","sequence":"additional","affiliation":[{"name":"From the Massachusetts General Hospital, Boston, MA; University of California at Los Angeles, Los Angeles; University of California at San Francisco, San Francisco; Western Clinical Research, Torrance, CA; University of Montreal, Montreal, Canada; University of Maryland, Baltimore, MD; S Florida Medical Research, Aventura, FL; Christchurch Hospital, Christchurch, New Zealand; Peter MacCallum Cancer Institute, Melbourne, Australia; Free University of Brussels, Brussels, Belgium; Novartis Oncology, East..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Schulman","sequence":"additional","affiliation":[{"name":"From the Massachusetts General Hospital, Boston, MA; University of California at Los Angeles, Los Angeles; University of California at San Francisco, San Francisco; Western Clinical Research, Torrance, CA; University of Montreal, Montreal, Canada; University of Maryland, Baltimore, MD; S Florida Medical Research, Aventura, FL; Christchurch Hospital, Christchurch, New Zealand; Peter MacCallum Cancer Institute, Melbourne, Australia; Free University of Brussels, Brussels, Belgium; Novartis Oncology, East..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Linnartz","sequence":"additional","affiliation":[{"name":"From the Massachusetts General Hospital, Boston, MA; University of California at Los Angeles, Los Angeles; University of California at San Francisco, San Francisco; Western Clinical Research, Torrance, CA; University of Montreal, Montreal, Canada; University of Maryland, Baltimore, MD; S Florida Medical Research, Aventura, FL; Christchurch Hospital, Christchurch, New Zealand; Peter MacCallum Cancer Institute, Melbourne, Australia; Free University of Brussels, Brussels, Belgium; Novartis Oncology, East..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zheng","sequence":"additional","affiliation":[{"name":"From the Massachusetts General Hospital, Boston, MA; University of California at Los Angeles, Los Angeles; University of California at San Francisco, San Francisco; Western Clinical Research, Torrance, CA; University of Montreal, Montreal, Canada; University of Maryland, Baltimore, MD; S Florida Medical Research, Aventura, FL; Christchurch Hospital, Christchurch, New Zealand; Peter MacCallum Cancer Institute, Melbourne, Australia; Free University of Brussels, Brussels, Belgium; Novartis Oncology, East..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Goessl","sequence":"additional","affiliation":[{"name":"From the Massachusetts General Hospital, Boston, MA; University of California at Los Angeles, Los Angeles; University of California at San Francisco, San Francisco; Western Clinical Research, Torrance, CA; University of Montreal, Montreal, Canada; University of Maryland, Baltimore, MD; S Florida Medical Research, Aventura, FL; Christchurch Hospital, Christchurch, New Zealand; Peter MacCallum Cancer Institute, Melbourne, Australia; Free University of Brussels, Brussels, Belgium; Novartis Oncology, East..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Jiang","family":"Hei","sequence":"additional","affiliation":[{"name":"From the Massachusetts General Hospital, Boston, MA; University of California at Los Angeles, Los Angeles; University of California at San Francisco, San Francisco; Western Clinical Research, Torrance, CA; University of Montreal, Montreal, Canada; University of Maryland, Baltimore, MD; S Florida Medical Research, Aventura, FL; Christchurch Hospital, Christchurch, New Zealand; Peter MacCallum Cancer Institute, Melbourne, Australia; Free University of Brussels, Brussels, Belgium; Novartis Oncology, East..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Small","sequence":"additional","affiliation":[{"name":"From the Massachusetts General Hospital, Boston, MA; University of California at Los Angeles, Los Angeles; University of California at San Francisco, San Francisco; Western Clinical Research, Torrance, CA; University of Montreal, Montreal, Canada; University of Maryland, Baltimore, MD; S Florida Medical Research, Aventura, FL; Christchurch Hospital, Christchurch, New Zealand; Peter MacCallum Cancer Institute, Melbourne, Australia; Free University of Brussels, Brussels, Belgium; Novartis Oncology, East..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Cook","sequence":"additional","affiliation":[{"name":"From the Massachusetts General Hospital, Boston, MA; University of California at Los Angeles, Los Angeles; University of California at San Francisco, San Francisco; Western Clinical Research, Torrance, CA; University of Montreal, Montreal, Canada; University of Maryland, Baltimore, MD; S Florida Medical Research, Aventura, FL; Christchurch Hospital, Christchurch, New Zealand; Peter MacCallum Cancer Institute, Melbourne, Australia; Free University of Brussels, Brussels, Belgium; Novartis Oncology, East..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celestia S.","family":"Higano","sequence":"additional","affiliation":[{"name":"From the Massachusetts General Hospital, Boston, MA; University of California at Los Angeles, Los Angeles; University of California at San Francisco, San Francisco; Western Clinical Research, Torrance, CA; University of Montreal, Montreal, Canada; University of Maryland, Baltimore, MD; S Florida Medical Research, Aventura, FL; Christchurch Hospital, Christchurch, New Zealand; Peter MacCallum Cancer Institute, Melbourne, Australia; Free University of Brussels, Brussels, Belgium; Novartis Oncology, East..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.54.1.8"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.1997.d01-6840.x"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199707313370502"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199912093412401"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041318"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040720"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"Kalbfleisch J, Prentice R: The Statistical Analysis of Failure Time Data (ed 2) . Indianapolis, IN, John Wiley and Sons, 2002","DOI":"10.1002\/9781118032985"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.17.1591"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.1.230"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)64238-1"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(11)62406-3"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(97)00082-5"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(00)00717-3"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.03.061"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djg043"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19981101)83:9<1989::AID-CNCR15>3.0.CO;2-V"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Mason MD, Collaborators MP: Development of bone metastases from prostate cancer: First results of the MRC PR04 trial (ISCRTN 61384873). Proc Am Soc Clin Oncol 22: 384S,2004,  (abstr 4511)","DOI":"10.1200\/jco.2004.22.90140.4511"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2005.01.529","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:03:52Z","timestamp":1653512632000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2005.01.529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5,1]]},"references-count":17,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2005,5,1]]}},"alternative-id":["10.1200\/JCO.2005.01.529"],"URL":"https:\/\/doi.org\/10.1200\/jco.2005.01.529","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,5,1]]}}}